PT1490490E - Oligómeros de bases nucleotídicas de iap anti-sentido e suas utilizações - Google Patents

Oligómeros de bases nucleotídicas de iap anti-sentido e suas utilizações Download PDF

Info

Publication number
PT1490490E
PT1490490E PT03715244T PT03715244T PT1490490E PT 1490490 E PT1490490 E PT 1490490E PT 03715244 T PT03715244 T PT 03715244T PT 03715244 T PT03715244 T PT 03715244T PT 1490490 E PT1490490 E PT 1490490E
Authority
PT
Portugal
Prior art keywords
nucleobase oligomers
antisense iap
iap nucleobase
antisense
oligomers
Prior art date
Application number
PT03715244T
Other languages
English (en)
Inventor
Eric Lacasse
Daniel Mcmanus
Jon P Durkin
Original Assignee
Aegera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc
Publication of PT1490490E publication Critical patent/PT1490490E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
PT03715244T 2002-03-27 2003-03-27 Oligómeros de bases nucleotídicas de iap anti-sentido e suas utilizações PT1490490E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36785302P 2002-03-27 2002-03-27

Publications (1)

Publication Number Publication Date
PT1490490E true PT1490490E (pt) 2009-07-13

Family

ID=28454856

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03715244T PT1490490E (pt) 2002-03-27 2003-03-27 Oligómeros de bases nucleotídicas de iap anti-sentido e suas utilizações

Country Status (17)

Country Link
US (5) US7091333B2 (pt)
EP (1) EP1490490B1 (pt)
JP (2) JP4486365B2 (pt)
CN (1) CN1656222B (pt)
AT (1) ATE431410T1 (pt)
AU (1) AU2003219432B2 (pt)
BR (1) BR0308923A (pt)
CA (1) CA2480308C (pt)
DE (1) DE60327618D1 (pt)
DK (1) DK1490490T3 (pt)
ES (1) ES2325660T3 (pt)
IL (2) IL164228A0 (pt)
MX (1) MXPA04009361A (pt)
NZ (3) NZ546806A (pt)
PT (1) PT1490490E (pt)
WO (1) WO2003080638A2 (pt)
ZA (1) ZA200407649B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
GB2406568B (en) * 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ES2325660T3 (es) 2002-03-27 2009-09-11 Aegera Therapeutics Inc. Oligomeros nucleobasicos de iap no codificantes y usos de los mismos.
US8586298B2 (en) * 2002-11-19 2013-11-19 Clluone Diagnostics A/S Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia
CA2524495A1 (en) * 2003-06-03 2005-01-13 Eli Lilly And Company Modulation of survivin expression
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
US20050148535A1 (en) * 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US8012944B2 (en) * 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP1713542A2 (en) * 2004-02-05 2006-10-25 Novartis AG COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
EP1586654A1 (en) 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replication competent viruses capable of silencing virus inhibitory factor expression
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1799859B1 (en) * 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US20080293653A1 (en) * 2004-10-14 2008-11-27 Jon Durkin Method of treating autoimmune diseases
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
JP2009508527A (ja) * 2005-09-19 2009-03-05 ジヨンソン・アンド・ジヨンソン・フアーマシユーチカル・リサーチ・アンド・デベロツプメント・エルエルシー グルココルチコイド受容体発現の調節
JP4557051B2 (ja) * 2008-06-17 2010-10-06 セイコーエプソン株式会社 プロジェクタ
EP3372684B1 (en) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Single-stranded rnai agents containing an internal, non-nucleic acid spacer
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
CN103906838A (zh) 2011-10-25 2014-07-02 Isis制药公司 Gccr表达的反义调节
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EP4056716A1 (en) * 2017-03-24 2022-09-14 Gen-Probe Incorporated Compositions and methods for detecting or quantifying parainfluenza virus
LU100182B1 (en) * 2017-04-06 2018-10-15 Univ Hamburg Eppendorf Uke Therapeutic use of microRNA 19A/19B
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
CN112673103A (zh) 2018-08-13 2021-04-16 阿尔尼拉姆医药品有限公司 乙型肝炎病毒(HBV)dsRNA剂组合物及其使用方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5594076A (en) 1991-09-24 1997-01-14 The Pennsylvania Research Foundation Hydrodegradable polyesters
US6265157B1 (en) * 1991-12-03 2001-07-24 Allegheny University Of The Health Sciences Compositions and methods for detecting altered COL1A1 gene sequences
US20030073159A1 (en) 1992-05-11 2003-04-17 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
WO1996035703A1 (en) 1995-05-11 1996-11-14 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
JP3562528B2 (ja) 1992-09-14 2004-09-08 ザ ジェネラル ホスピタル コーポレイション Ｉｋａｒｏｓ：ｔ細胞経路調節遺伝子
US6087173A (en) * 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US5958772A (en) 1998-12-03 1999-09-28 Isis Pharmaceuticals Inc. Antisense inhibition of cellular inhibitor of apoptosis-1 expression
US5958771A (en) 1998-12-03 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of cellular inhibitor of Apoptosis-2 expression
AU6586494A (en) 1993-04-14 1994-11-08 United States Of America As Represented By The Secretary Of The Navy, The Transgenic animal model for autoimmune diseases
US5691179A (en) 1993-08-26 1997-11-25 Washington University Cell death regulators
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
EP0770129B1 (en) 1994-01-18 2005-11-23 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
WO1995028497A1 (en) 1994-04-13 1995-10-26 La Jolla Cancer Research Foundation Interaction of proteins involved in a cell death pathway
WO1995030435A2 (en) 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6020127A (en) 1994-10-18 2000-02-01 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
IL115766A0 (en) 1994-10-25 1996-01-19 Immulogic Pharma Corp Composition and treatment for multiple sclerosis
WO1996020950A2 (en) 1995-01-06 1996-07-11 Immulogic Pharmaceutical Corporation Compositions and methods for treating rheumatoid arthritis
US5770690A (en) 1995-06-27 1998-06-23 Neurex Corporation Bax omega protein and methods
US5877021A (en) * 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US5919912A (en) * 1995-08-04 1999-07-06 University Of Ottawa Mammalian IAP antibodies and diagnostic kits
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU6692996A (en) 1995-08-08 1997-03-05 Tularik Inc. Inhibitors of apoptosis
US6187557B1 (en) * 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
US5834216A (en) 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
AUPN727595A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
US5605022A (en) * 1995-12-26 1997-02-25 Nci Building Systems, Inc. Vented closure
GB9601108D0 (en) 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
WO1998022131A2 (en) 1996-11-15 1998-05-28 University Of Ottawa Modulators of ovarial apoptosis related to iap
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US6228603B1 (en) 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
CA2225187A1 (en) 1997-07-14 1999-01-14 Universite D'ottawa/ University Of Ottawa Xaf genes and polypeptides: methods and reagents for modulating apoptosis
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
AU1080899A (en) 1997-10-14 1999-05-03 Nadine A. Tatton Methods for increasing schwann cell survival
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU757034B2 (en) * 1998-04-27 2003-01-30 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
US6171821B1 (en) * 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
EP1117391A2 (en) 1998-10-09 2001-07-25 L. Sai Latha Shankar Methods for treating multiple sclerosis
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
KR20000065690A (ko) 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
US6395771B1 (en) 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6673917B1 (en) * 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
US20020119168A1 (en) 2001-02-20 2002-08-29 Rudnic Edward M. Therapeutic agent delivery
KR100397275B1 (ko) * 2001-03-08 2003-09-17 주식회사 웰진 단방향성 안티센스 ｃＤＮＡ 라이브러리 구축을 통한 신규대규모 유전자 검색 및 기능 분석 시스템
AU2003228301A1 (en) 2002-03-06 2003-09-22 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of sirna molecules
ES2325660T3 (es) 2002-03-27 2009-09-11 Aegera Therapeutics Inc. Oligomeros nucleobasicos de iap no codificantes y usos de los mismos.
EP1469070A1 (en) 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Livin-specific siRNAs for the treatment of therapy-resistant tumors
US7579455B2 (en) 2003-09-29 2009-08-25 Topigen Pharmaceutique Inc. Oligonucleotide compositions and methods for treating disease including inflammatory conditions
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent

Also Published As

Publication number Publication date
BR0308923A (pt) 2005-01-04
EP1490490B1 (en) 2009-05-13
NZ546806A (en) 2007-03-30
ES2325660T3 (es) 2009-09-11
WO2003080638A9 (en) 2003-11-27
US20030190659A1 (en) 2003-10-09
EP1490490A2 (en) 2004-12-29
WO2003080638A3 (en) 2004-05-21
ZA200407649B (en) 2006-07-26
JP2005528891A (ja) 2005-09-29
NZ546807A (en) 2007-03-30
NZ535461A (en) 2007-03-30
DK1490490T3 (da) 2009-09-07
AU2003219432A1 (en) 2003-10-08
AU2003219432B2 (en) 2010-04-01
CA2480308C (en) 2011-10-04
DE60327618D1 (de) 2009-06-25
CN1656222A (zh) 2005-08-17
ATE431410T1 (de) 2009-05-15
US20070049544A1 (en) 2007-03-01
US20070135371A1 (en) 2007-06-14
US7091333B2 (en) 2006-08-15
IL164228A0 (en) 2005-12-18
US7638497B2 (en) 2009-12-29
JP4486365B2 (ja) 2010-06-23
JP2010042009A (ja) 2010-02-25
IL164228A (en) 2011-06-30
MXPA04009361A (es) 2005-05-17
CN1656222B (zh) 2011-11-30
US7638620B2 (en) 2009-12-29
US20070032445A1 (en) 2007-02-08
CA2480308A1 (en) 2003-10-02
WO2003080638A2 (en) 2003-10-02
US20070178064A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
IL164228A0 (en) Antisense iap nucleobase oligomers and uses thereof
NL301145I1 (pt)
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
TW200637522A (en) Skin treatment articles and methods
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2003097794A3 (en) Universal-tagged oligonucleotide primers and methods of use
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
IL186104A0 (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
MX2007014132A (es) Compuestos de diarilhidantoina.
EP1569695A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
WO2004112687A3 (en) Antiviral acylguanidine compounds and methods
MY144616A (en) Substituted dihydroquinazolines
EP1667685A4 (en) INHIBITORS OF QUINAZOLINE-BASED POTASSIUM CANAL
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
PL1843771T3 (pl) Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2
GB9924941D0 (en) Treatment of dyskinesia
MY166063A (en) Intravenous antiviral treatments
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
EP2021023A4 (en) MUTANTS OF MYXOMA VIRUS FOR THE TREATMENT OF CANCER
UA85187C2 (en) 2-aminobenzoyl derivatives
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
WO2004014299A3 (en) Antisense modulation of resistin expression